Temperature-sensitive hydrogel vaccine based on KIF20A protein as well as preparation method and application of temperature-sensitive hydrogel vaccine

Through the thermosensitive hydrogel vaccine based on KIF20A protein, combining liposomes and PLGA-PEG-PLGA triblock copolymer, the problem of poor antigen immune activation effect of existing HCC vaccines is solved, and more efficient immune activation and liver cancer are achieved The therapeutic effect has enhanced the efficacy of PD-L1 blockade treatment.

CN119074912APending Publication Date: 2024-12-06ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411132909.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing hepatocellular carcinoma (HCC) vaccine antigens such as alpha-fetoprotein, phosphatidylinositol-3 and telomerase-like reverse transcriptase have poor immune activation effects and are difficult to meet the long-term survival needs of middle and late-stage patients. , and the KIF20A polypeptide vaccine has limited effect due to HLA subtype limitation and single antigen epitope.

Method used

Using a thermosensitive hydrogel vaccine based on KIF20A protein, the co-delivery of liposomes and PLGA-PEG-PLGA triblock copolymer hydrogel is optimized, and the vaccine performance is enhanced, and the immune activation efficiency is enhanced. Combined with the immune adjuvant R848, antigen and immunity are achieved. Synchronous delivery of adjuvants stimulates stronger anti-tumor immune response.

Benefits of technology

It significantly enhanced the efficacy and objective remission rate of PD-L1 blockade treatment, improved the activation and immune response of CD8+ T cells, provided a wider range of antigen epitopes, overcome the limitations of the peptide vaccine, and achieved more efficient Hepatocellular carcinoma vaccine effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074912A_ABST
    Figure CN119074912A_ABST
Patent Text Reader

Abstract

The invention provides a temperature-sensitive hydrogel vaccine based on KIF20A protein, a preparation method and application, and belongs to the technical field of biologication.The hepatocellular carcinoma vaccine is constructed based on the KIF20A protein, the performance of the vaccine is reasonably optimized by co-delivering liposome Vac and temperature-sensitive hydrogel, the immune activation efficiency of the vaccine is improved, the in-vivo vaccine slow-release effect is improved, and the effect of treating the hepatocellular carcinoma is achieved. Finally, evaluation proves that the prepared KIF20A protein vaccine has a good effect in the aspect of enhancing the PD-L1 blocking treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to the preparation of a liver cancer vaccine, and in particular to a temperature-sensitive hydrogel vaccine based on KIF20A protein, a preparation method and an application thereof. Background Art

[0002] The incidence of liver cancer ranks sixth among all malignant tumors and the mortality rate ranks third worldwide. Hepatocellular carcinoma (HCC) is the most common histological type of liver cancer, accounting for more than 80% [1] In China, the incidence of primary liver cancer ranks fourth among malignant tumors and the mortality rate ranks second, which seriously endangers the lives and health of the people.

[0003] PD-1 / L1 blockade therapy is an important way to treat HCC systemically. Its clinical efficacy is generally better than targeted therapy and chemotherapy, but it still cannot meet the long-term survival needs of patients with advanced HCC. Therefore, enhancing the efficacy of PD-1 / L1 immune checkpoint blockade therapy and improving the objective response rate are of great significance to improving the prognosis of patients with advanced HCC. This is not only a clinical problem that needs to be solved urgently, but also a major clinical need.

[0004] Tumor vaccine is a new type of tumor immunotherapy, which aims to stimulate the body's immune system to attack and kill tumor cells. Currently, there are many clinical trials of tumor vaccines underway around the world. Therefore, tumor vaccine is a kind of tumor vaccine that can effectively activate CD8 + Therapeutic methods that can activate T cell function and have broad clinical transformation prospects. However, the antigens currently used in HCC vaccine clinical trials, such as alpha-fetoprotein (AFP), glypican-3 (GPC3), and human telomerase reverse transcriptase (hTERT), are generally not particularly ideal in terms of immune activation effects. Therefore, the discovery of more effective vaccine antigens is an urgent need.

[0005] Kinesin Family Member 20A (KIF20A), also known as MKLP2 (Mitotic Kinesin-Like Protein 2), is a microtubule motor protein. KIF20A plays an important role in cell division, especially in the late stage of mitosis, where it participates in cytoplasmic division (organelle distribution) and centrosome positioning. In HCC, the expression level of KIF20A is significantly increased, and is associated with a high degree of HCC malignancy, poor prognosis, and low survival rate. Previous studies by our research group have pointed out that KIF20A promotes chromosomal instability in HCC, thereby mediating the malignant biological behavior of HCC. KIF20A is highly expressed in HCC cells and less expressed in normal tissues. It is a relatively new TAA, and its vaccine is also used to treat a variety of malignant tumors, but there has been no research on the therapeutic effect on HCC. At present, although there are related studies using KIF20A peptide as a tumor vaccine, it is only targeted at a single human leukocyte antigen (HLA) subtype restricted epitope, which is difficult to be widely promoted in the population. In addition, peptides only provide a single antigenic epitope and can often only activate a single immune response, while an effective immune response usually requires B cells, CD4 + and CD8 + Therefore, previous studies on KIF20A polypeptide vaccines were not ideal. The use of KIF20A protein has stronger immunogenicity and can provide more antigenic epitopes. Therefore, using the entire protein as an antigen can overcome the limitations of polypeptides to a certain extent.

[0006] As a synthetic phospholipid vesicle, liposomes have been approved for clinical use by the US and China Food and Drug Administration. They are a safe, stable and widely applicable delivery platform. In addition, liposomes have good targeting to lymph nodes and can protect antigens from premature degradation and loss of immunogenicity. Therefore, loading KIF20A protein and immune adjuvant R848 into liposomes to achieve simultaneous delivery of antigens and immune adjuvants can not only improve drug distribution to a certain extent, but also improve the delivery efficiency of antigens and immune adjuvants to lymph nodes, and more efficiently stimulate anti-tumor immune responses.

[0007] Hydrogels also show broad prospects in the construction of vaccines. Hydrogels are a three-dimensional cross-linked network structure that allows hydrogels to retain a large amount of water while maintaining a specific volume and shape. In addition, through different designs, hydrogels can exhibit different mechanical strengths, porosities, and self-healing properties, and can also respond to changes in the external environment, such as temperature, pH, and concentration, which makes them show broad prospects in drug controlled release. In recent years, hydrogels have been widely used in the field of vaccines. They can not only protect the effective ingredients of vaccines, but also slowly release antigens, avoiding the nonspecific distribution of vaccines in the body, thereby minimizing adverse side effects and maximizing immune responses. It is a research hotspot for the new generation of tumor vaccines. Summary of the invention

[0008] In view of the above problems, the purpose of the present invention is to provide a thermosensitive hydrogel vaccine based on KIF20A protein, a preparation method and an application thereof, to construct an HCC vaccine based on KIF20A protein, and to further rationally optimize the vaccine performance by co-delivering liposomes and thermosensitive hydrogels to enhance its immune activation efficiency.

[0009] The specific scheme adopted by the present invention is:

[0010] In a first aspect, the present invention provides a method for preparing a thermosensitive hydrogel vaccine based on KIF20A protein, comprising the following steps: Step 1: Synthesis of co-delivery liposome Vac Weigh DOTAP, cholesterol and DSPE-PEG2000 respectively, dissolve them in chloroform, disperse them evenly with ultrasound, take a certain amount in a round-bottom flask, add R848, and after fully dissolving, vacuum rotary evaporation is performed at 40°C until the solvent is completely evaporated, then add chloroform and repeat the rotary evaporation step; after the rotary evaporation is completed, a thin film is formed on the inner wall of the round-bottom flask; take the KIF20A protein aqueous solution, and hydrate it by ultrasound in a water bath for 1 minute; absorb the obtained solution into a liposome extruder, and push the liposomes through polycarbonate membranes with pore sizes of 200 nm and 100 nm at 40°C respectively; then, add the obtained solution into a nanodialysis device for dialysis for 12 hours; finally, wash out the solution, add water to make up the volume, transfer it to a glass bottle, and freeze-dry it to obtain the co-delivery liposome Vac; Step 2: Synthesis of PLGA-PEG-PLGA triblock copolymer hydrogel Take a clean three-necked round-bottom flask, add a magnetic stirrer, then add PEG1500, connect the oil pump, evacuate, pass nitrogen, and remove residual oxygen in the bottle; then heat to 120°C in an oil bath and stir for 30 minutes to fully melt PEG1500; turn on the oil pump to evacuate, and continue heating at 120°C for 2 hours to completely remove any moisture that may exist in PEG1500; weigh DL-lactide and glycolide, transfer to a fume hood, pass nitrogen into the round-bottom flask, quickly add the weighed DL-lactide and glycolide into the bottle, and plug the bottle; evacuate to remove moisture and oxygen in the bottle, and heat at 120°C 30 minutes to dissolve DL-lactide and glycolide and fully mix with PEG1500; use a syringe to draw stannous octoate, inject it into a round-bottom flask, seal the tube, and raise the temperature to 150°C and maintain it for 8 hours; after the reaction cools to room temperature, add dichloromethane to the round-bottom flask to fully dissolve the crude product, and transfer it to a flat-bottom flask, add petroleum ether to precipitate, filter, and redissolve the obtained solid in dichloromethane, add petroleum ether to precipitate and filter to obtain a high-purity PLGA-PEG-PLGA triblock copolymer, and dry the obtained solid in a vacuum environment for 24 hours to constant weight and store it for use; Step 3: KIF20A thermosensitive hydrogel vaccine CSF-Vac Gel Preparation The co-delivery liposome Vac was loaded into the thermosensitive hydrogel to prepare the thermosensitive hydrogel vaccine CSF-Vac. Gel , the specific steps are as follows: ① Dissolve the PLGA-PEG-PLGA triblock copolymer obtained in step 2 in ultrapure water, stir at 4°C for 24 hours, and then add mouse granulocyte-macrophage colony stimulating factor GM-CSF to obtain CSF Gel , store at 4℃ until use; ②To CSF Gel The co-delivery liposome Vac powder obtained in step 1 was added to the mixture and vortexed to disperse it evenly to obtain the KIF20A thermosensitive hydrogel vaccine CSF-Vac. Gel .

[0011] As a further optimization of the above preparation method, in step 1, the molar ratio of DOTAP, cholesterol and DSPE-PEG2000 is 50:4:5.

[0012] As a further optimization of the above preparation method, in step 2, the molar ratio of DL-lactide to glycolide is 3:1.

[0013] As a further optimization of the above preparation method, in step 3, ①, the mass percentage of PLGA-PEG-PLGA triblock copolymer is 15%, and the concentration of GM-CSF is 10 μg / mL; in step 3, ②, the concentration of co-delivery liposome Vac is 1 mg / mL.

[0014] In a second aspect, the present invention provides a thermosensitive hydrogel vaccine prepared by the above-mentioned preparation method.

[0015] The third aspect is the application of the above-mentioned thermosensitive hydrogel vaccine in the preparation of liver cancer vaccine drugs.

[0016] Beneficial effects: The present invention prepares a liver cancer vaccine based on KIF20A protein, optimizes vaccine performance through liposomes and PLGA-PEG-PLGA triblock copolymer hydrogel, and is used to enhance the efficacy of PD-L1 blocking therapy. Specific advantages are: 1. Co-delivery of KIF20A protein and immune adjuvant R848 through liposomes to enhance the immune activation effect; 2. PLGA-PEG-PLGA triblock copolymer thermosensitive hydrogel achieves sustained release effect in vivo; 3. The above hydrogel vaccine enhanced the therapeutic effect of PD-L1 blockade in mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 .Schematic diagram of the synthesis of PLGA-PEG-PLGA triblock copolymer.

[0018] Figure 2 .Nuclear magnetic resonance (NMR) hydrogen spectrum of PLGA-PEG-PLGA triblock copolymer.

[0019] Figure 3 .(A)CSF-Vac Gel Photos at 25°C and 37°C. (B) Hydrogel micelles shown by environmental scanning electron microscopy (scale bar is 100 μm). (C) Vac liposome particles loaded in hydrogel (scale bar is 50 μm). (D) Changes in storage modulus G' and loss modulus G" from rheological measurements under temperature changes. (E) Changes in storage modulus G' and loss modulus G" over time at 37°C.

[0020] Figure 4 (A) Gel group, aPD-L1 group, CSF-Vac Gel Group and aPD-L1+CSF-Vac Gel (B) Changes in tumor volume of mice in different groups. (C) Changes in body weight of mice in different groups during treatment. ***: p<0.001, ****: p<0.0001.

[0021] Figure 5 .HE pathological sections of tumor. Scale bar: 50μm.

[0022] Figure 6 (A) Bioluminescence images of mice during treatment. (B) Changes in tumor bioluminescence signals of each mouse in each group. (C) Quantification of the average tumor bioluminescence signal of each group. (D) Body weight quantification. ns: no significant difference, **: p<0.01, ****: p<0.0001.

[0023] Figure 7 .(A)CD45 + CD3 + Gating. (B) CD3 in different groups + Representative flow cytometry plots of CD8a and CD4 expression in cells.

[0024] Figure 8 .(A)CD45 + CD3 + CD8a + The proportion of cells. (B) CD45 + CD3 + CD4 + The proportion of cells. (C)CD45 + CD3 + CD8a + / CD4 + The ratio of cells. ns: no significant difference, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.

[0025] Fig. 9 .(A)CD11 + Gating strategy for single cell population. (B) CD80 + and CD86 + Cell distribution.

[0026] Fig.10 .CD80 + CD86 + CD11c + Quantitative analysis of cell ratios. ns: no significant difference, *: p<0.05, **: p<0.01.

[0027] Fig.11 .CD11c measured by flow cytometry + Results of CD40, CD80 and CD86 expression in cells.

[0028] Fig.12 .CD11c + CD40+ (A) CD80 + (B) and CD86 + (C) Quantitative analysis results of cell ratios.

[0029] Fig.13 (A) Subcutaneous injection of indocyanine green (ICG), ICG@Vac and ICG@Vac Gel (B) Quantitative analysis of fluorescence intensity.

[0030] Fig.14 .CSF-Vac Gel Flowchart of treatment for PD-L1 blockade (aPD-L1).

[0031] Fig.15 .Schematic diagram of sustained release of hydrogel after injection. DETAILED DESCRIPTION

[0032] Liver cancer vaccines can effectively enhance the therapeutic effect and objective remission rate of PD-L1 blockade therapy. This patent constructs an HCC vaccine based on KIF20A protein, further optimizes the vaccine performance by co-delivering liposomes and thermosensitive hydrogels, enhances its immune activation efficiency, and finally evaluates the effect of KIF20A protein vaccine in enhancing the efficacy of PD-L1 blockade therapy.

[0033] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention and the accompanying drawings.

[0034] In the following examples and comparative examples, unless otherwise specified, the materials or reagents used are conventionally commercially available, and the operations or methods used are conventional technical means.

[0035] Example

[0036] 1. Vaccine preparation steps

[0037] (1) Synthesis of co-delivery liposome Vac

[0038] Weigh 28 mg DOTAP (Aladdin, D292990), 1.3 mg cholesterol (Aladdin, C104032) and 11.2 mg DSPE-PEG2000 (Aladdin, D163634) (molar weight of about 50:4:5) on an electronic balance, dissolve in 40.5 mL chloroform, disperse evenly by ultrasonication, take to a 10 mL round-bottom flask, add 0.5 mg R848 (Aladdin, R131891), and after fully dissolved, vacuum evaporation at 40 ° C until the solvent is completely evaporated, then add 5 mL chloroform and repeat the evaporation step. After the evaporation is completed, remove the round-bottom flask, and a thin film can be seen on the inner wall of the flask. Take 2 mL of a 50 μg / mL KIF20A protein (Abmart, RG511068) aqueous solution and hydrate it by ultrasonication for 1 minute in a water bath. Subsequently, the resulting solution was sucked into a liposome extruder (Avanti Polar Lipids), and the liposomes were pushed through polycarbonate membranes (Millipore) with pore sizes of 200 nm and 100 nm at 40°C. Subsequently, the resulting solution was dialyzed in a nanodialysis device (Whatman polycarbonate membrane, 30 nm pore size) for 12 hours. Finally, the solution was washed out, fixed to 5 mL with water, transferred to a glass bottle, and freeze-dried in a freeze dryer for 24 hours. The resulting liposome powder was stored at -20°C for use.

[0039] (2) Synthesis of PLGA-PEG-PLGA triblock copolymer hydrogel

[0040] Take a clean 250mL three-necked round-bottom flask and add a magnetic stirrer. Then add 60g PEG1500 (Aladdin, P103721). Apply an appropriate amount of high vacuum grease to the side of the rubber stopper, and then plug it into the bottle mouth on both sides to prevent air leakage. Then apply high vacuum grease to the interface of the glass joint, connect the other end of the joint to a double-row tube, vacuum the oil pump for 10 minutes, and then introduce nitrogen, repeat 3 times to completely eliminate the residual oxygen in the bottle. Then heat to 120°C in an oil bath and stir for 30 minutes to fully melt the PEG. Then turn on the oil pump to vacuum, and continue heating at 120°C for 2 hours to completely remove the moisture that may exist in PEG1500. Then, weigh 113.46g of DL-lactide (Aladdin, S161100) and 30.48g of glycolide (Aladdin, G156824) (molar ratio of 3:1) and transfer to a fume hood. Nitrogen was introduced into the round-bottom flask, the nitrogen flow was increased and the stopper on one side was opened to reduce the mixing of oxygen. The weighed DL-lactide and glycolide were quickly added into the bottle and the stopper was plugged. The oil pump was turned on again to evacuate the bottle to remove the water and oxygen that may be mixed into the bottle, and the DL-lactide and glycolide were dissolved and fully mixed with PEG1500. Subsequently, 0.04g of stannous octoate (Macklin, T818482) was drawn with a syringe, injected into the round-bottom flask, the tube was sealed, and the temperature was raised to 150°C for 8 hours. After the reaction was cooled to room temperature, 40ml of dichloromethane was added to the round-bottom flask to fully dissolve the crude product, and transferred to a 1L flat-bottom flask, 500mL of petroleum ether was added to precipitate, filtered, and the obtained solid was redissolved in 40mL of dichloromethane, 500mL of petroleum ether was added to precipitate and filtered. The above steps were repeated three times to obtain a high-purity PLGA-PEG-PLGA triblock copolymer. The obtained solid was dried in a vacuum environment for 24 hours to a constant weight, and stored at -20°C in a light-proof, water-free environment for later use.

[0041] Figure 1 Schematic diagram of the synthesis of PLGA-PEG-PLGA triblock copolymer.

[0042] (3) KIF20A thermosensitive hydrogel vaccine (CSF-Vac Gel )

[0043] We loaded Vac into the thermosensitive hydrogel to prepare the thermosensitive hydrogel vaccine CSF-Vac. Gel , the specific steps are as follows:

[0044] ① Dissolve the PLGA-PEG-PLGA triblock copolymer in ultrapure water to a mass percentage of 15%, stir the solution at 4°C for 24 hours, and then add mouse granulocyte-macrophage colony stimulating factor (GM-CSF) to a concentration of 10 μg / mL to obtain CSF Gel , store at 4℃ until use.

[0045] ②To CSF Gel Add an appropriate amount of Vac powder to make the concentration 1 mg / mL, vortex to make it evenly dispersed, and obtain KIF20A thermosensitive hydrogel vaccine (CSF-Vac Gel In addition, in order to set up a control group in some experiments, we also synthesized Vac Gel Vac was dispersed in 15% PLGA-PEG-PLGA triblock copolymer solution at a concentration of 1 mg / mL and vortexed to obtain Vac Gel .

[0046] 2. Experimental results

[0047] (1) CSF-Vac Gel Characterization

[0048] 1 H-NMR spectrum suggests the successful synthesis of PLGA-PEG-PLGA ( Figure 2 ). We are Gel The prepared hydrogel vaccine is a thermosensitive hydrogel, which is liquid at 25°C and undergoes a phase change at 37°C, solidifying into a solid state ( Figure 3 A). We used environmental electron scanning microscopy to characterize CSF-Vac Gel The morphology of CSF-Vac was characterized. Gel Micelles ( Figure 3 B), by magnifying the field of view, Vac liposome particles loaded in the hydrogel can be seen ( Figure 3 C), then, we used rheometer to analyze the CSF-Vac Gel Mechanical properties were characterized. Temperature scanning ( Figure 3 D) shows that as the temperature increases, the storage modulus G' gradually exceeds the loss modulus G", and the intersection of the two is 36.17℃, indicating that the hydrogel vaccine will transform from liquid to solid when the temperature is higher than 36.17℃, which is conducive to its solidification after subcutaneous injection in mice, and then achieve slow release. Time scan (( Figure 3 E) shows that during the test time of 0-6 minutes, the storage modulus G' is always greater than the loss modulus G", and as time goes by, there is no obvious change in G' and G", indicating that the hydrogel is stable after the phase transition.

[0049] (2) Treatment of subcutaneous liver cancer model

[0050] To validate the hydrogel vaccine CSF-Vac Gel The enhancement effect of vaccination on the efficacy of PD-L1 blockade therapy was investigated by monitoring the changes in tumor size in different treatment groups using a subcutaneous liver cancer tumor model. The control group (Control) received no drug treatment, the PD-L1 blockade group (aPD-L1) received intraperitoneal injection of PD-L1 monoclonal antibody, and the vaccine group (CSF-Vac Gel ) Subcutaneous injection of hydrogel vaccine CSF-Vac Gel , combined treatment group (aPD-L1+CSF-Vac Gel ) were given intraperitoneally and CSF-Vac Gel After drug treatment, the photos of mice and quantitative analysis of tumor volume showed that the tumor volume of the control group continued to increase, while that of the aPD-L1 group and the CSF-Vac Gel Although the tumor volume of the aPD-L1+CSF-Vac group increased, its growth rate was slower than that of the control group. Gel The tumor volume was significantly reduced in the Figure 4 ).

[0051] We performed HE and immunofluorescence staining on liver cancer tissues. HE staining showed that the nuclei of tumor cells were large and obvious, and the cells were arranged tightly and disorderly ( Figure 5 ). aPD-L1 group and CSF-Vac Gel In the group, the infiltration of immune cells increased, the nuclei of some tumor cells disappeared, and the aPD-L1+CSF-Vac Gel A large number of lymphocytes were observed in the group, and tumor cells were basically invisible, suggesting that aPD-L1+CSF-Vac Gel The combined treatment not only promoted the infiltration of a large number of lymphocytes in tumor tissues, but also produced the maximum tumor killing effect.

[0052] (3) Treatment of hepatocellular carcinoma in situ model

[0053] Based on the subcutaneous hepatocellular carcinoma, we further monitored the growth of orthotopic hepatocellular carcinoma in different groups of mice by bioluminescence imaging ( Figure 6 A), Control group, aPD-L1 group, CSF-Vac Gel The bioluminescence signals of all groups increased to varying degrees, except for aPD-L1+CSF-Vac Gel The quantitative results showed that the change trend of tumor signal intensity of each mouse in the four groups was basically the same. The signal enhancement in the Control group was the fastest, followed by the aPD-L1 group, and the CSF-Vac Gel The aPD-L1+CSF-Vac group was relatively slow, while GelThe signal intensity of the group was significantly reduced, and the quantification of the average tumor signal intensity of 4 mice in each group also showed similar results ( Figure 6 B and C). During the treatment, no significant weight changes were observed in the mice in each group ( Figure 6 D).

[0054] We used flow cytometry to analyze immune cells in mouse tumor tissue, peripheral blood, spleen, and lymph nodes. + CD3 + T cell analysis ( Figure 7 A) shows that in the control group, T cells in tumor tissue were CD4 + Cells are the main ones. After drug treatment, CD8a + The proportion of T cells increased significantly, indicating a significant infiltration of cytotoxic T cells ( Figure 7 B). Quantitative analysis showed that the control group, aPD-L1 group, and CSF-Vac Gel Group and aPD-L1+CSF-Vac Gel CD8a + CD45 + CD3 + The proportions were 33.8%, 77.13%, 78.5% and 83.63% respectively ( Figure 8 A), CD4 + CD45 + CD3 + The proportions were 54.33%, 12.17%, 12.1% and 6.41% respectively ( Figure 8 B), CD8a + Cells and CD4 + The ratios of cell numbers were 0.62, 6.34, 6.49, and 13.17 ( Figure 8 C). The above results suggest that in aPD-L1, Vac Gel Both can effectively increase T cell infiltration in HCC and increase CD8a + The proportion of cytotoxic T cells.

[0055] We also studied the status of dendritic cells in the lymph nodes of each group of mice. + In single cell populations ( Fig. 9 A), CSF-Vac Gel Treatment group CD80 + CD86 + The proportion of cells increased significantly ( Fig. 9 B). Quantitative results showed that the control group, aPD-L1 group, and CSF-Vac Gel Group and aPD-L1+CSF-VacGel Group CD80 + CD86 + The proportions of CD11c+ cells were 22.57%, 24.80%, 34.47% and 36.07% respectively ( Fig.10 ). This suggests that aPD-L1 has little effect on dendritic cells, and CSF-Vac Gel It can effectively promote the maturation of dendritic cells.

[0056] Comparison Example

[0057] (1) The effect of co-delivery liposome Vac was better than that of the group without liposomes

[0058] Flow cytometry results of primary bone marrow-derived dendritic cells showed that CD11c + In the cells, the proportion of CD40+, CD80+ and CD86+ cells increased significantly in the liposome Vac group ( Fig.11 ). Quantitative results showed that the proportions of CD40+, CD80+, and CD86+ cells in the liposome Vac group were significantly higher than those in the R848+KIF20A group without liposomes ( Fig.12 A, B and C), indicating that under the action of the same components, the co-delivery effect of KIF20A and R848 brought by liposomes significantly enhanced the immune activation effect of the vaccine.

[0059] (2) Hydrogel provides better sustained-release effect for vaccines

[0060] In order to verify the sustained release effect of hydrogel, we put ICG, ICG@Vac and ICG@Vac Gel The ICG signal intensity at the injection site was monitored using NIR-II fluorescence imaging. Fig.13 A). Quantitative results show that ( Fig.13 B) After subcutaneous injection, the signal of small molecule ICG decreased rapidly within 24 hours, indicating that the metabolism rate of small molecule ICG subcutaneously injected was the fastest. The metabolism of nanoscale ICG@Vac subcutaneously was slower than that of small molecule ICG. Hydrogel ICG@Vac Gel The slowest signal attenuation was shown subcutaneously, suggesting that the hydrogel vaccine has the best sustained-release effect and is conducive to long-term stimulation of the lymph nodes.

[0061] like Fig.14 As shown in the treatment process, the liver cancer vaccine (CSF-Vac Gel ) activates the body's T cell function, thereby enhancing the therapeutic effect of PD-L1 blockade (aPD-L1) therapy.

[0062] like Fig.15As shown in the figure, the hydrogel prepared based on PLGA-PEG-PLGA triblock copolymer changes from liquid to solid at 37°C. Therefore, the liver cancer vaccine (CSF-VacGel) in liquid state at room temperature can be injected subcutaneously. Under the action of body temperature, the hydrogel gradually changes from solid to solid, thereby achieving a sustained release effect.

[0063] It should be noted that the above-described embodiments should be understood as illustrative rather than limiting the scope of protection of the present invention, and the scope of protection of the present invention shall be subject to the claims. For those skilled in the art, some non-essential improvements and adjustments made to the present invention still fall within the scope of protection of the present invention without departing from the essence and scope of the present invention.

Claims

1. A method for preparing a thermosensitive hydrogel vaccine based on KIF20A protein, characterized in that: The following steps are involved: Step 1: Synthesis of co-delivery liposome Vac Weigh (2,3-dioleyloxypropyl)trimethylammonium chloride (DOTAP), cholesterol and phospholipid-polyethylene glycol 2000 (DSPE-PEG2000) respectively, dissolve them in chloroform, disperse them evenly by ultrasonication, take a certain amount in a round-bottom flask, add R848, and after fully dissolving, vacuum rotary evaporation is performed at 40°C until the solvent is completely evaporated, then chloroform is added and the rotary evaporation step is repeated; after the rotary evaporation is completed, a thin film is formed on the inner wall of the round-bottom flask; take the KIF20A protein aqueous solution and hydrate it by ultrasonication in a water bath for 1 minute; absorb the obtained solution into a liposome extruder, and push the liposomes through polycarbonate membranes with pore sizes of 200 nm and 100 nm at 40°C respectively; then, add the obtained solution into a nanodialysis device for dialysis for 12 hours; finally, wash out the solution, add water to make up the volume, transfer it to a glass bottle, and freeze-dry it to obtain the co-delivery liposome Vac; Step 2: Synthesis of PLGA-PEG-PLGA triblock copolymer hydrogel Take a clean three-necked round-bottom flask, add a magnetic stirrer, then add PEG1500, connect an oil pump, evacuate and introduce nitrogen to remove residual oxygen in the bottle; then heat to 120°C in an oil bath and stir for 30 minutes to fully melt PEG1500; turn on the oil pump to evacuate again, heat at 120°C for 2 hours to completely remove any moisture that may exist in PEG1500; weigh DL-lactide and glycolide, transfer to a fume hood, introduce nitrogen into the round-bottom flask, quickly add the weighed DL-lactide and glycolide into the bottle, and plug the bottle; evacuate to remove moisture and oxygen in the bottle, heat at 120°C for 30 minutes to dissolve DL-lactide and glycolide and fully mix with PEG1500 under stirring; use a syringe to draw stannous octoate, inject it into a round-bottom flask, seal the tube, raise the temperature to 150°C, and maintain it for 8 hours; after the reaction cools to room temperature, add dichloromethane to the round-bottom flask to fully dissolve the crude product, and transfer it to a new flat-bottom flask, add petroleum ether to precipitate, filter, and redissolve the obtained solid in dichloromethane, add petroleum ether to precipitate and filter to obtain a high-purity PLGA-PEG-PLGA triblock copolymer, and dry the obtained solid in a vacuum environment for 24 hours to constant weight and store it for use; Step 3: KIF20A thermosensitive hydrogel vaccine CSF-Vac Gel Preparation The co-delivery liposome Vac was loaded into the thermosensitive hydrogel to prepare the thermosensitive hydrogel vaccine CSF-Vac. Gel , the specific steps are as follows: ① Dissolve the PLGA-PEG-PLGA triblock copolymer obtained in step 2 in ultrapure water, stir at 4°C for 24 hours, and then add mouse granulocyte-macrophage colony stimulating factor (GM-CSF) to obtain CSF Gel , store at 4℃ until use; ②To CSF Gel The co-delivery liposome Vac powder obtained in step 1 was added to the mixture and vortexed to disperse it evenly to obtain the KIF20A thermosensitive hydrogel vaccine CSF-Vac. Gel .

2. The preparation method according to claim 1, characterized in that: In step 1, the molar ratio of DOTAP, cholesterol and DSPE-PEG2000 is 50:4:

5.

3. The preparation method according to claim 1, characterized in that: In step 2, the molar ratio of DL-lactide to glycolide is 3:

1.

4. The preparation method according to claim 1, characterized in that: In step 3, ①, the mass percentage of PLGA-PEG-PLGA triblock copolymer is 15%, and the concentration of GM-CSF is 10 μg / mL; in step 3, ②, the concentration of co-delivery liposome Vac is 1 mg / mL.

5. The thermosensitive hydrogel vaccine prepared according to the preparation method according to any one of claims 1 to 4.

6. Use of the thermosensitive hydrogel vaccine according to claim 5 in the preparation of liver cancer vaccine drugs.